Dr Paul Slowey

Paul Tri-Con 2017

CEO – Oasis Diagnostics Corporation

Dr. Slowey is the Founder and Owner of Oasis Diagnostics® Corporation and its subsidiary Company, Bamburgh Marrsh LLC, founded in 2002, each are pioneers in the area of oral fluid diagnostics and testing. Dr Slowey’s background is in Organic Chemistry; after being awarded his Doctorate from the University of Newcastle-upon-Tyne (UK), he spent several years as a Post Doctoral Fellow in Canada then 5 years in the pharmaceutical industry with Sterling Drug [UK].  He has over 32 years of experience in the clinical diagnostic and pharmaceutical industries combined. Over the years he has held positions as Director of International Sales and Chief Operating Officer (COO) and Vice President of Sales and Marketing for companies that were the original pioneers in the development of saliva diagnostic rapid tests for infectious diseases, and oral fluid collection devices. He has extensive experience in structuring strategic alliances and license agreements with both start-up and Fortune 500 companies. Dr Slowey has 30 publications in peer-reviewed journals, fifteen (15) issued patents, twelve (12) filed patent applications and he has made a number of oral presentations at key scientific symposia on a variety of subjects including HIV diagnosis, nucleic acid testing, the status of oral fluid testing, the Japanese Healthcare Business and Thyrotropin Receptor Antibody Assays for the Diagnosis of Graves’ Disease.

Dr Slowey is the Founder and Co-Organizer of the North American Saliva Symposium [NASS, www.salivasymposium.com ] and is a Director of a small teaching college in Kampala, Uganda. In recognition of his work in the field Dr Slowey was recently made an Honorary Professor to Central South University, in Changsha, Hunan Province, China.

Presentation Title: Saliva- the Ideal Specimen for Liquid Biopsy?

Tissue biopsy remains the gold standard for cancer diagnosis, but recent developments have shown that blood biopsies targeting cell free RNA, circulating tumor DNA, exosomes and protein fragments, can be useful as adjuncts to tissue testing, particularly for monitoring purposes, treatment response and other applications.  Saliva represents the ideal non-invasive specimen for liquid biopsy testing, but can this unique biofluid be used alongside blood, or as a stand-alone biological specimen for cancer testing and diagnosis?